Employee infections and production disruptions caused by a serious infectious disease
First written in FY2020. 10 of 11 entries say "Restated". Latest entry: FY2026-H1.
The whole theme swung hardest in 2025: 2 of 13 companies on the "Worse" side.
25 other companies' latest entry also says "Restated".
- FY2026-H1RestatedAnnual report
「During the interim consolidated accounting period, there were no new business risks and no material changes to the business risks described in the annual securities report for the previous fiscal year.」
The filing states that there have been no material changes regarding the risk of employee infections and production disruptions caused by a serious infectious disease. - FY2024RestatedAnnual report
「If a serious infectious disease similar to COVID-19 were to spread rapidly and persist for an extended period, the Group's employees could become infected on a widespread basis, and the interruption of production activities could affect the Group's results.」
The risks of employee infections, production disruptions and an impact on earnings caused by a serious infectious disease are reaffirmed. - FY2024-Q3RestatedAnnual report
「During the nine-month period ended in the third quarter, there was no occurrence of any new business or other risk, nor any material change in the business or other risks described in the annual securities report for the previous fiscal year.」
The filing states that there have been no material changes regarding the risk of employee infections and production disruptions caused by a serious infectious disease. - FY2024-Q1RestatedAnnual report
「During the cumulative first quarter under review, there were no newly arising business or other risks, nor any material changes to the business or other risks described in the securities report for the preceding fiscal year.」
The filing states that there have been no material changes regarding the risk of employee infections and production disruptions caused by a serious infectious disease. - FY2023-Q3RestatedAnnual report
「During the nine-month cumulative period of the current fiscal year, there were no new business or other risks, nor any material changes to the business or other risks described in the annual securities report for the previous fiscal year. The impact of COVID-19 on the business will continue to be monitored closely in light of future developments.」
No material changes are indicated regarding the risk of employee infections and production disruptions caused by a serious infectious disease, and the business impact will continue to be monitored. - FY2022RestatedAnnual report
「If a serious infectious disease such as COVID-19 were to spread rapidly and persist for an extended period, the Group's employees could become infected on a widespread basis, and the interruption of production activities could affect the Group's results.」
The risks of employee infections, production disruptions and an impact on earnings caused by a serious infectious disease are reaffirmed. - FY2022-Q2RestatedAnnual report
「During the six-month cumulative period of the current fiscal year, there were no new business or other risks, nor any material changes to the business or other risks described in the annual securities report for the previous fiscal year. The impact of COVID-19 on the business will continue to be monitored closely in light of future developments.」
No new material changes are indicated regarding the risk of employee infections and production disruptions caused by a serious infectious disease, and the business impact of infectious diseases will continue to be monitored. - FY2022-Q1RestatedAnnual report
「During the three-month cumulative period of the current fiscal year, there were no new business or other risks, nor any material changes to the business or other risks described in the annual securities report for the previous fiscal year. The impact of COVID-19 on the business will continue to be monitored closely in light of future developments.」
No new material changes are indicated regarding the risk of employee infections and production disruptions caused by a serious infectious disease, and the business impact of infectious diseases will continue to be monitored. - FY2021-Q2RestatedAnnual report
「During the six-month cumulative period of the current fiscal year, there were no new business or other risks, nor any material changes to the business or other risks described in the annual securities report for the previous fiscal year. The impact of COVID-19 on the business will continue to be monitored closely in light of future developments.」
No new material changes are indicated regarding the risk of employee infections and production disruptions caused by a serious infectious disease, and the business impact of infectious diseases will continue to be monitored. - FY2021-Q1RestatedAnnual report
「During the three-month cumulative period of the current fiscal year, there were no new business or other risks, nor any material changes to the business or other risks described in the annual securities report for the previous fiscal year. The impact of COVID-19 on the business will continue to be monitored closely in light of future developments.」
No new changes are indicated regarding the risk of employee infections and production disruptions caused by a serious infectious disease, and the business impact of infectious diseases will continue to be monitored. - FY2020First statedAnnual report
「If a serious infectious disease such as COVID-19 were to spread rapidly and persist for an extended period, the Group's employees could become infected on a widespread basis, and the interruption of production activities could affect the Group's results.」
The possibility that a serious infectious disease could cause widespread employee infections and interrupt production activities is described as a new business and other risk.